Search Results 571-580 of 18379 for alopecia

1. Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides - Mayo Clinic

   ... alopecia and ≤Grade 2 peripheral neuropathy. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 (Appendix B). Life expectancy ≥12 weeks ...

2. A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis - Mayo Clinic

   Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia;; Women of child bearing potential (WCBP), defined ...

3. A Study Of Amivantamab In Combination With Lazertinib, Or Amivantamab In Combination With Platinum-Based Chemotherapy, For Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) - Mayo Clinic

   ... alopecia \[any grade\], grade \<=2 peripheral neuropathy, or grade \<=2 hypothyroidism stable on hormone replacement) * Have an eastern cooperative oncology ...

4. A Study to Test the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors - Mayo Clinic

   The patient must have recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all prior therapies except alopecia, neuropathy and other non ...

5. Pediatric dermatology - Overview - Mayo Clinic

   Atopic dermatitis (eczema). Birthmarks, such as hemangioma and port-wine stain. Connective tissue disorders of the skin. Contact dermatitis. Dermatoses of ...

6. A Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy in Patients with Gastric or Gastroesophageal Cancer - Mayo Clinic

   alopecia, neuropathy, and specific laboratory abnormalities). 29. Administration of a live vaccine within 28 days before first dose of study drug. 30 ...

7. Ph 1b Study to Evaluate GSK2110183 in Combination with Bortezomib and Dexamethasone in Subjects with Multiple Myeloma - Mayo Clinic

   Unresolved toxicity (except alopecia) ≥ Grade 2 National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 [NCI ...

8. A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma - Mayo Clinic

   ... alopecia and decreased tendon reflex and to ≤ Grade 1 for all other effects at the time of enrollment, unless otherwise noted. Consult with the Lilly ...

9. Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma - Mayo Clinic

   Patients should have resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute (NCI) Common Terminology Criteria for ...

10. A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma - Mayo Clinic

    Subject has not fully recovered from the acute toxicities (except alopecia) of any prior anti-cancer therapy. Subject requiring concomitant use of strong ...